71 results
6-K
EX-10.2
MREO
Mereo Biopharma Group Plc
19 Feb 20
Mereo BioPharma Announces Equity Investment of $3 Million from New U.S. Institutional Investor
9:32am
, preparing or defending any action, claim, suit, inquiry, proceeding, investigation or appeal taken from the foregoing by or before any court … . Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the Indemnified Person and shall survive
6-K
EX-1.1
MREO
Mereo Biopharma Group Plc
10 Feb 21
Mereo BioPharma Group plc Announces Proposed Public Offering of American Depositary Shares
5:23pm
of any term of any such Authorizations; (D) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation … such claim, litigation, arbitration, action, suit, investigation or proceeding; (E) has not received notice that the FDA or any Governmental Authority has
F-4
EX-10.17
MREO
Mereo Biopharma Group Plc
25 Jan 19
Registration of securities (foreign)
12:00am
.
If the action or conduct of any Participant, Group Member or relevant business unit is under investigation prior to the third anniversary of the Grant Date … applying to an Award pursuant to this rule 6 and such investigation has not yet been concluded by that date, the period referred to in rules 6.2, 6.3
F-4
EX-10.16
MREO
Mereo Biopharma Group Plc
25 Jan 19
Registration of securities (foreign)
12:00am
to the Award.
If the action or conduct of any Participant, Group Member or relevant business unit is under investigation prior to the second … anniversary of the last day of the Performance Period applying to an Award pursuant to this rule 7 and such investigation has not yet been concluded
S-8
EX-99.4
MREO
Mereo Biopharma Group Plc
15 Jan 21
Registration of securities for employees
4:21pm
to the Award.
If the action or conduct of any Participant, Group Member or relevant business unit is under investigation prior to the third anniversary … of the Grant Date applying to an Award pursuant to this rule 6 and such investigation has not yet been concluded by that date, the period referred
6-K
zqpeb0hz2 pild
30 May 19
Current report (foreign)
12:09pm
S-8
EX-99.5
p6eb3kg to4jx
15 Jan 21
Registration of securities for employees
4:21pm
6-K
EX-10.2
zo6fo3zvkt 41k
10 Feb 20
Current report (foreign)
7:20am
6-K
EX-99.1
357ae0bpxprf6lqrv
9 May 22
Current report (foreign)
8:06am
6-K
EX-10.2
mq42q6t22h5m 2uhm8n
5 Jun 20
Mereo BioPharma Announces Completion of $70 Million Private Placement
12:00am
6-K
EX-99.1
64wubquqcer qhkd7
22 Nov 19
Current report (foreign)
9:29am
6-K
EX-99.1
sp3m4kk
30 Nov 21
Mereo BioPharma Reports Interim Data from ACTIVATE Phase 1b/2 Open Label Study of
7:51am
6-K
EX-99.1
w5hvu7az l1gfl3
26 Oct 21
Mereo BioPharma Receives U.S. Orphan Drug Designation for alvelestat in About Mereo BioPharma
10:07am
S-8
EX-5.1
p3d2qku84rin mh
21 May 19
Registration of securities for employees
1:53pm
F-3
EX-1.2
ppq xv7dvyco
6 Oct 20
Shelf registration (foreign)
4:25pm
S-3
EX-1.2
n2bocp
15 May 24
Shelf registration
4:49pm
F-3
EX-1.2
vcmppvpnq2 ql0oec
5 Aug 21
Shelf registration (foreign)
4:33pm
F-4
EX-5.1
jxsqu8e5h7
25 Jan 19
Registration of securities (foreign)
12:00am
6-K
EX-99.1
7kbn5t yivcy
17 Sep 19
Current report (foreign)
8:06am
10-K
EX-19.1
94we4qxnlso tiqc
27 Mar 24
Annual report
5:20pm